$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000106282214000044 Filed on November 06, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q4
Revenue	$21.48M	$419.0K	$1.410M
YoY Change	1423.55%	76.05%	546.79%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.000M	$4.500M	$3.400M
YoY Change	17.65%	-4.26%	-12.82%
% of Gross Profit
Research & Development	$20.00M	$24.11M	$20.30M
YoY Change	-1.48%	-5.09%	-3.33%
% of Gross Profit
Depreciation & Amortization	$200.0K	$500.0K	$700.0K
YoY Change	-71.43%	-16.67%	-22.22%
% of Gross Profit
Operating Expenses	$24.90M	$40.76M	$18.40M
YoY Change	35.33%	29.57%	-25.51%
Operating Profit	-$3.447M	-$40.34M	-$16.98M
YoY Change	-79.69%	29.22%	-30.69%
Interest Expense	-$900.0K	$449.0K	-$500.0K
YoY Change	80.0%	-8.74%	0.0%
% of Operating Profit
Other Income/Expense, Net	$1.300M	$287.0K	$0.00
YoY Change		2509.09%	-100.0%
Pretax Income	-$3.000M	-$40.50M	-$17.40M
YoY Change	-82.76%	27.76%	-30.12%
Income Tax	-$100.0K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.933M	-$40.50M	-$17.41M
YoY Change	-83.16%	27.92%	-29.99%
Net Earnings / Revenue	-13.65%	-9665.39%	-1235.04%
Basic Earnings Per Share
Diluted Earnings Per Share	-$34.16K	-$551.0K	-$237.1K
COMMON SHARES
Basic Shares Outstanding	514.8M shares	514.8M shares	513.5M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$338.9M	$57.40M	$128.7M
YoY Change	163.33%	-61.94%	-42.24%
Cash & Equivalents	$137.3M	$26.78M	$37.50M
Short-Term Investments	$201.6M	$30.70M	$91.20M
Other Short-Term Assets	$4.764M	$5.937M	$4.636M
YoY Change	2.76%	-18.19%	-26.98%
Inventory
Prepaid Expenses
Receivables	$1.035M	$165.0K	$790.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$369.0M	$87.82M	$134.6M
YoY Change	174.23%	-44.89%	-41.74%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.080M	$1.494M	$41.36M
YoY Change	-97.39%	-96.43%	-2.98%
Goodwill	$44.54M	$44.54M	$44.54M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$53.36M	$53.56M	$53.56M
YoY Change	-0.37%	0.0%	0.0%
Long-Term Investments
YoY Change
Other Assets	$3.409M	$108.0K	$144.0K
YoY Change	2267.36%	-31.65%	32.11%
Total Long-Term Assets	$102.4M	$99.70M	$139.6M
YoY Change	-26.66%	-28.83%	-0.88%
TOTAL ASSETS
Total Short-Term Assets	$369.0M	$87.82M	$134.6M
Total Long-Term Assets	$102.4M	$99.70M	$139.6M
Total Assets	$471.4M	$187.5M	$274.2M
YoY Change	71.93%	-37.38%	-26.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.06M	$9.741M	$9.715M
YoY Change	34.47%	0.33%	26.81%
Accrued Expenses	$10.12M	$13.13M	$7.674M
YoY Change	31.87%	13.92%	-13.99%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$20.17M	$20.61M	$1.710M
YoY Change	1079.36%	1130.39%	8.64%
Total Short-Term Liabilities	$44.97M	$44.27M	$19.29M
YoY Change	133.07%	87.6%	5.52%
LONG-TERM LIABILITIES
Long-Term Debt	$87.50M	$0.00	$20.17M
YoY Change	333.88%	-100.0%	-7.82%
Other Long-Term Liabilities	$23.54M	$34.01M	$32.39M
YoY Change	-27.33%	-9.06%	0.32%
Total Long-Term Liabilities	$111.0M	$34.01M	$52.55M
YoY Change	111.28%	-41.37%	-2.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$44.97M	$44.27M	$19.29M
Total Long-Term Liabilities	$111.0M	$34.01M	$52.55M
Total Liabilities	$187.4M	$109.7M	$104.0M
YoY Change	80.16%	-3.56%	-1.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.104B	-$1.101B	-$1.004B
YoY Change	9.99%	11.63%	11.57%
Common Stock	$104.0K	$516.0K	$514.0K
YoY Change	-79.77%	0.39%	0.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.390M	$2.390M	$1.503M
YoY Change	59.02%	59.02%	138.57%
Treasury Stock Shares	183.0K shares	1.281M shares	814.0K shares
Shareholders Equity	$284.0M	$77.82M	$170.2M
YoY Change
Total Liabilities & Shareholders Equity	$471.4M	$187.5M	$274.2M
YoY Change	71.93%	-37.38%	-26.26%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q4
OPERATING ACTIVITIES
Net Income	-$2.933M	-$40.50M	-$17.41M
YoY Change	-83.16%	27.92%	-29.99%
Depreciation, Depletion And Amortization	$200.0K	$500.0K	$700.0K
YoY Change	-71.43%	-16.67%	-22.22%
Cash From Operating Activities	-$4.400M	-$21.20M	-$21.80M
YoY Change	-79.82%	-11.3%	6.34%
INVESTING ACTIVITIES
Capital Expenditures	-$100.0K	$0.00	-$200.0K
YoY Change	-50.0%	-100.0%	100.0%
Acquisitions
YoY Change
Other Investing Activities	-$170.6M	$20.50M	$40.00M
YoY Change	-526.5%	0.0%	-706.06%
Cash From Investing Activities	-$170.7M	$20.50M	$39.70M
YoY Change	-529.97%	0.99%	-692.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	285.7M	-300.0K	-100.0K
YoY Change	-285800.0%		-100.27%
NET CHANGE
Cash From Operating Activities	-4.400M	-21.20M	-21.80M
Cash From Investing Activities	-170.7M	20.50M	39.70M
Cash From Financing Activities	285.7M	-300.0K	-100.0K
Net Change In Cash	110.6M	-1.000M	17.80M
YoY Change	521.35%	-72.22%	85.42%
FREE CASH FLOW
Cash From Operating Activities	-$4.400M	-$21.20M	-$21.80M
Capital Expenditures	-$100.0K	$0.00	-$200.0K
Free Cash Flow	-$4.300M	-$21.20M	-$21.60M
YoY Change	-80.09%	-10.17%	5.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9715000	USD
CY2014Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	9741000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	790000	USD
CY2014Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	165000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7674000	USD
CY2014Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13134000	USD
CY2014Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	48743000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	81945000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2000	USD
CY2014Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1175108000	USD
CY2014Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1181015000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5584000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5728000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5700000	USD
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1500000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5600000	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1800000	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2014Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	13100000	USD
CY2013Q4	us-gaap	Assets Assets	274160000	USD
CY2014Q3	us-gaap	Assets Assets	187522000	USD
CY2014Q3	us-gaap	Assets Current AssetsCurrent	87820000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	134554000	USD
CY2014Q3	us-gaap	Assets Held For Sale Long Lived Fair Value Disclosure AssetsHeldForSaleLongLivedFairValueDisclosure	23800000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37499000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26775000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19581000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30423000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10842000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10724000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	514000	USD
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	516000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31651000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40501000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-86697000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-97361000	USD
CY2013Q3	us-gaap	Contracts Revenue ContractsRevenue	238000	USD
	us-gaap	Contracts Revenue ContractsRevenue	1111000	USD
	us-gaap	Contracts Revenue ContractsRevenue	733000	USD
CY2014Q3	us-gaap	Contracts Revenue ContractsRevenue	312000	USD
CY2014Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0823
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	195000	USD
CY2014Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	785000	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13405000	USD
CY2014Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	12679000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18745000	USD
CY2014Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18745000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1724000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2194000	USD
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
	us-gaap	Investment Income Interest InvestmentIncomeInterest	17000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	518000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	3079000	USD
CY2012Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	29920000	USD
CY2014Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	28228000	USD
CY2013Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	32999000	USD
CY2013Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	27710000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	811000	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4716000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13709000	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4617000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15423000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2014Q3	us-gaap	Goodwill Goodwill	44543000	USD
CY2014Q3	us-gaap	Guarantee Obligations Maximum Exposure GuaranteeObligationsMaximumExposure	4000000	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	13344000	USD
CY2013Q3	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	0	USD
CY2014Q3	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	13102000	USD
	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	13102000	USD
	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	0	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6587000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6684000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-483000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-625000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	136000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-52000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	62000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	63000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1301000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-69338000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-908000	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53557000	USD
CY2014Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53557000	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	449000	USD
	us-gaap	Interest Expense InterestExpense	1494000	USD
	us-gaap	Interest Expense InterestExpense	1361000	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	492000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1355000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1437000	USD
CY2013Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	39000	USD
CY2014Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	5000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	136000	USD
CY2014Q3	us-gaap	Liabilities Liabilities	109698000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	103997000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	274160000	USD
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	187522000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19294000	USD
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	44269000	USD
	us-gaap	Licenses Revenue LicensesRevenue	79000	USD
CY2013Q3	us-gaap	Licenses Revenue LicensesRevenue	0	USD
	us-gaap	Licenses Revenue LicensesRevenue	261000	USD
CY2014Q3	us-gaap	Licenses Revenue LicensesRevenue	107000	USD
CY2014Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	20609000	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1710000	USD
CY2014Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	20167000	USD
CY2004Q2	us-gaap	Mortgage Loans On Real Estate New Mortgage Loans MortgageLoansOnRealEstateNewMortgageLoans	34000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1857000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1277000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	59773000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	62297000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	20651000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	46000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-71164000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-31658000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-40498000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-86712000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-97361000	USD
	us-gaap	Operating Expenses OperatingExpenses	86207000	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	40755000	USD
	us-gaap	Operating Expenses OperatingExpenses	98291000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	31454000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-31216000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-96919000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-85395000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-40336000	USD
CY2014Q3	us-gaap	Other Assets Current OtherAssetsCurrent	5937000	USD
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4636000	USD
CY2014Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	108000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	144000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	7000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-3000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	15000	USD
CY2014Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	34005000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	32386000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	41000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	902000	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	282000	USD
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11000	USD
	us-gaap	Other Restructuring Costs OtherRestructuringCosts	400000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	873000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	887000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	80954000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1506000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	325000	USD
CY2014Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	874000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-111000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-27000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	142125000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	81186000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	108000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1808000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41362000	USD
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1494000	USD
CY2014Q3	us-gaap	Real Estate Heldforsale RealEstateHeldforsale	23849000	USD
CY2013Q4	us-gaap	Real Estate Heldforsale RealEstateHeldforsale	0	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1268000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1167000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	69248000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24108000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	69419000	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25400000	USD
CY2013Q4	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2014Q3	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2014Q3	us-gaap	Restructuring And Related Cost Cost Incurred To Date1 RestructuringAndRelatedCostCostIncurredToDate1	5600000	USD
	us-gaap	Restructuring Costs RestructuringCosts	5700000	USD
CY2014Q3	us-gaap	Restructuring Reserve RestructuringReserve	400000	USD
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1101319000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1003958000	USD
	us-gaap	Revenues Revenues	1372000	USD
CY2013Q3	us-gaap	Revenues Revenues	238000	USD
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	814000	shares
CY2014Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	1281000	shares
CY2014Q3	us-gaap	Treasury Stock Value TreasuryStockValue	2390000	USD
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1503000	USD
CY2014Q3	us-gaap	Revenues Revenues	419000	USD
	us-gaap	Revenues Revenues	812000	USD
CY2014Q3	us-gaap	Secured Debt SecuredDebt	20600000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5584000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5728000	USD
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	91629000	USD
CY2014Q3	us-gaap	Short Term Investments ShortTermInvestments	31094000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	874000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	325000	USD
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	77824000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	170163000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	170163000	USD
CY2013Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	185710000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	266678000	USD
CY2014Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	77824000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	887000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	873000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	15000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	514461000	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	513419000	shares
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	514796000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	512980000	shares
CY2013Q3	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	1338000	USD
CY2014Q3	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	-1072000	USD
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	518000	USD
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	3079000	USD
CY2007Q2	lxrx	Holdings Contribution To Icon HoldingsContributionToIcon	45000000	USD
CY2014Q4	lxrx	Ipsen Regulatory And Commercial Launch Milestones IpsenRegulatoryAndCommercialLaunchMilestones	30000000	USD
CY2014Q4	lxrx	Ipsen Sales Milestones IpsenSalesMilestones	72000000	EUR
CY2014Q4	lxrx	Ipsen Upfront Payment IpsenUpfrontPayment	23000000	USD
CY2010Q3	lxrx	Lexicon Paid Holdings Cash LexiconPaidHoldingsCash	10000000	USD
CY2007Q2	lxrx	Lexicon Received Cash From Holdings LexiconReceivedCashFromHoldings	15000000	USD
CY2007Q2	lxrx	Lexicon Sold Shares To Holdings LexiconSoldSharesToHoldings	7650622	shares
	lxrx	Restructuring Cost Severance Costs RestructuringCostSeveranceCosts	5300000	USD
	lxrx	Restructuringand Related Costs Cost Incurredto Date Generaland Administrative RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative	700000	USD
	lxrx	Restructuringand Related Costs Cost Incurredto Date Researchand Development RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment	4900000	USD
	lxrx	Restructuringand Related Costs Cost Incurredto Date Stockbased Compensation RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation	100000	USD
	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod	102560	shares
	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue	1.56
	lxrx	Sharebased Compensation Arrangementby Sharebased Payment Award Stock Bonusand Restricted Stockto Consultants Grantsin Period SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod	57400	shares
	lxrx	Sharebased Compensation Arrangementby Sharebased Payment Award Stock Bonusand Restricted Stockto Consultants Grantsin Period Weighted Average Grant Date Fair Value SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue	1.60
	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	2349000	USD
CY2014Q3	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	697000	USD
	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	2389000	USD
CY2013Q3	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	723000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	3379000	USD
CY2014Q3	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	797000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	3195000	USD
CY2013Q3	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1027000	USD
CY2010Q3	lxrx	Symphon Fair Value Of Base And Contingent Payments SymphonFairValueOfBaseAndContingentPayments	45600000	USD
CY2010Q3	lxrx	Symphony Base Payment Discount Rate SymphonyBasePaymentDiscountRate	0.14
CY2012Q3	lxrx	Symphony Base Payment In Shares SymphonyBasePaymentInShares	13237519	shares
CY2012Q3	lxrx	Symphony Base Payment Obligation SymphonyBasePaymentObligation	35000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Discount Rate SymphonyContingentPaymentDiscountRate	0.18
CY2010Q3	lxrx	Symphony Contingent Payment Maximum SymphonyContingentPaymentMaximum	45000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Percentage SymphonyContingentPaymentPercentage	0.50
CY2010Q3	lxrx	Symphony Payment In Stock Limitation SymphonyPaymentInStockLimitation	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Payment SymphonyRegulatoryApprovalPayment	15000000	USD
CY2010Q3	lxrx	Symphony Regulatory Approval Percentage Limit SymphonyRegulatoryApprovalPercentageLimit	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Reduction Percentage SymphonyRegulatoryApprovalReductionPercentage	0.50
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	514834527	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	LEXICON PHARMACEUTICALS, INC./DE

Files In Submission

Name	View Source	Status
0001062822-14-000044-index-headers.html	Edgar Link	pending
0001062822-14-000044-index.html	Edgar Link	pending
0001062822-14-000044.txt	Edgar Link	pending
0001062822-14-000044-xbrl.zip	Edgar Link	pending
exh101licenseandcollaborat.htm	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lx1032.jpg	Edgar Link	pending
lx1033a01.jpg	Edgar Link	pending
lx1606.jpg	Edgar Link	pending
lxrx-20140930.xml	Edgar Link	completed
lxrx-20140930.xsd	Edgar Link	pending
lxrx-20140930_cal.xml	Edgar Link	unprocessable
lxrx-20140930_def.xml	Edgar Link	unprocessable
lxrx-20140930_lab.xml	Edgar Link	unprocessable
lxrx-20140930_pre.xml	Edgar Link	unprocessable
lxrx930201410-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2014 Q4 Form 10-Q Financial Statement

#000106282214000044 Filed on November 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2014 Q4 Form 10-Q Financial Statement

#000106282214000044 Filed on November 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx